8-K filed Aug 13, 2026 at 16:59 ET
Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply lower operating expenses as the company maintains a lean cash-burn structure while evaluating acquisition and in-licensing opportunities. Cash and marketable securities stood at $69.9M, down from $76.3M at year-end 2025, but management expects this to fund operations beyond 2027. The filing is routine for a pre-revenue biotech with no pipeline catalysts, the stock's direction hinges entirely on whether a transaction materializes, not on the quarterly loss trajectory.